Trifluoroacetic acid → HCID 178487623, compound
Reaction equation
C([NH:8][C:9]([N:18]1[CH:22]=[CH:21][CH:20]=N1)=[N:10]C(OC(C)(C)C)=O)(OC(C)(C)C)=O.NCCC[CH2:27][CH2:28][O:29][C:30]1[C:31]([O:50][CH3:51])=[CH:32][CH:33]=[C:34]2[C:39]=1[O:38][C:37](=[O:40])[CH:36]=[C:35]2[NH:41][C:42]1[C:47]([Cl:48])=[CH:46][N:45]=[CH:44][C:43]=1[Cl:49].FC(F)(F)C(O)=O>ClCCl>[Cl:49][C:43]1[CH:44]=[N:45][CH:46]=[C:47]([Cl:48])[C:42]=1[NH:41][C:35]1[C:34]2[C:39](=[C:30]([O:29][CH2:28][CH2:27][CH2:20][CH2:21][CH2:22][NH:18][C:9]([NH2:8])=[NH:10])[C:31]([O:50][CH3:51])=[CH:32][CH:33]=2)[O:38][C:37](=[O:40])[CH:36]=1Participants
Reactant 3
Product 1
Reagents, catalysts & solvents 1
Procedure
N,N′-Di-Boc-1H-pyrazole-1-carboxamidine (40 mg, 0.13 mmol) was added to a mixture of 8-(5-aminopentyloxy)-4-(3,5-dichloropyridin-4-ylamino)-7-methoxy-2H-chromen-2-one (40 mg, 0.09 mmol, Example 68) and dichloromethane (3 mL). After stirring for 30 min, trifluoroacetic acid (0.3 mL) was added. After an additional 19 h, the reaction was concentrated and purified by reverse-phase HPLC (1:9→3:2; acetonitrile:water) to give to give 1-(5-(4-(3,5-dichloropyridin-4-ylamino)-7-methoxy-2-oxo-2H-chromen-8-yloxy)pentyl)guanidine: 1H NMR (400 MHz, DMSO-d6; HCl salt): δ 9.60 (s, 1H), 8.82 (s, 2H), 7.98 (d, 1H), 7.57 (t, 1H), 7.50-6.70 (br, 4H), 7.21 (d, 1H), 4.63 (s, 1H), 3.98 (t, 2H), 3.92 (s, 3H), 3.11 (m, 2H), 1.70 (m, 2H), 1.52 (m, 4H); MS (ESI): 479.9.
Workup
- waitAfter an additional 19 h
- concentrationthe reaction was concentrated
- custompurified by reverse-phase HPLC (1:9→3:2; acetonitrile:water)
- customto give
Sources & evidence
- ORD record
- ord-542c2b3b218c4b90895df7cd7c66887d
- Source dataset
- uspto-grants-2010_06
- Patent number
- US07745646B2
Reaction notes
Loading…